Please assess the completion status of the following clinical trial:

Trial Title: Effects of Liraglutide on the Cognitive Function in Patients With Type 2 Diabetes Mellitus

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Type 2 diabetes。~Exclusion Criteria:~* Type 2 diabetes with acute diabetic complications.~* Type 1 diabetes.~* Other diseases affecting cognitive function (congenital dementia,brain trauma,severe heart dysfunction,severe kidney dysfunction,severe lung dysfunction,epilepsy,severe hypoglycemic coma,cerebrovascular disease,ischemic heart disease,etc).~* Alcohol abuse,mental illness and psychoactive substance abuse.~* History of thyroid disease.~* Any surgical or medical conditions that significantly influence absorption, distribution, metabolism or excretion of the intervention drugs.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Liraglutide (Type: ACTIVE_COMPARATOR): 12 weeks of liraglutide treatment at adjusting dose, up to 1.8mg/day Drug: liraglutide
- Placebo (Type: PLACEBO_COMPARATOR): 12 weeks of Placebo treatment at adjusting dose Drug:Placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).